Rini et al. announced that one treatment-related death due to increased blood creatinine and c-reactive protein (CRP) was reported in the sorafenib group of the AXIS (Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma) study [17]. Here, CRP is linked to hereditary clear cell renal cell carcinoma.